Given that genetic and pharmacological interventions of these CTSs exerted a beneficial effect on autoimmune diseases in model mice [120, 122], therapy with small CTS inhibitors might help lower the incidence and mortality of ACVD patients with and without autoimmune disease. This evidence concerns the gene TTR and autoimmune disease.